<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154568">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01723891</url>
  </required_header>
  <id_info>
    <org_study_id>HT-002-01</org_study_id>
    <nct_id>NCT01723891</nct_id>
  </id_info>
  <brief_title>Study To Compare Safety and Pharmacokinetic Properties of Surfolase Capsule and HT-002-01 in Healthy Male Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyundai Pharmaceutical Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hyundai Pharmaceutical Co., LTD.</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to compare safety and pharmacokinetic properties of surfolase capsule and HT-002-01
      after oral administration for one day in healthy male volunteer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUCt, Cmax</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf, Tmax, t1/2</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Surfolase capsule &amp; HT-002-01</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HT-002-01 &amp; Surfolase capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surfolase capsule</intervention_name>
    <arm_group_label>Surfolase capsule &amp; HT-002-01</arm_group_label>
    <arm_group_label>HT-002-01 &amp; Surfolase capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HT-002-01</intervention_name>
    <arm_group_label>Surfolase capsule &amp; HT-002-01</arm_group_label>
    <arm_group_label>HT-002-01 &amp; Surfolase capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. healthy male subjects between the age of 20 and 55 years with body mass index between
             18.5 and 25

          2. Volunteers without apriority of chronic disease

          3. Volunteers must be in good health as determined by the investigator based on a
             detailed medical history, full physical examination, electrocardiogram, laboratory
             tests and urinalysis

          4. Volunteers who comply with the protocol, understand and sign an informed consent

        Exclusion Criteria:

          1. Sensitive response to acebrophylline and xanthine

          2. Galactose intolerance, Lapp lactase deficiency and Glucose-Galactose Malabsorption

          3. Known history of renal, hepatic, respiratory, neurologic, endocrine, cardiac vascular
             and hematopoietic disease, especially gallstone

          4. Known history of gastrointestinal disease which affects the absorption of medicine.

          5. Excluded by screening tests

          6. Upper limit of AST, ALT&gt;1.25 times Upper limit of total bilirubin&gt;1.5 times

          7. Estimated GFR&lt;80mL/min/1.73m2)

          8. systolic blood pressure &lt; 90 or &gt; 150, diastolic blood pressure &lt;50 or &gt;100

          9. Known history of drug abuse

         10. caffeine&gt;5cups/day, alcohol&gt;210g/week, 10 more cigarettes/day

         11. Use of any prescription drug within 14days or over-the-counter (OTC) medication
             within 7 days prior to dosing

         12. Participation in any clinical investigation within 60 days prior to study start

         13. Donation of blood within 60 days, donation of component blood within 30days

         14. Judged by the investigators to be undesirable as subjects
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 7, 2012</lastchanged_date>
  <firstreceived_date>November 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
